Clinical Trials at Beacon Kalamazoo
As of August 2026, 35 paid clinical trials are recruiting at Beacon Kalamazoo, located at Beacon Kalamazoo - Formerly Borgess Hospital, 1521 Gull Rd, Kalamazoo, MI 49048, phone (269) 226-7000 in Kalamazoo, Michigan. Active studies at this site cover conditions such as Malignant Solid Neoplasm, Acute Myeloid Leukemia and Anatomic Stage II Breast Cancer AJCC v8. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
35 clinical trials at Beacon Kalamazoo
·Clear filters·Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Mobile Health for Adherence in Breast Cancer Patients
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Project: Every Child for Younger Patients With Cancer
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Common conditions studied in Kalamazoo
- Malignant Solid Neoplasm (5 active studies)
- Acute Myeloid Leukemia (4 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- B Acute Lymphoblastic Leukemia (4 active studies)
- Lung Non-Small Cell Carcinoma (4 active studies)
- Advanced Lung Non-Small Cell Carcinoma (3 active studies)
Leading research sponsors in Kalamazoo
- National Cancer Institute (NCI)
- Children's Oncology Group
- SWOG Cancer Research Network
- NRG Oncology
- Alliance for Clinical Trials in Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Kalamazoo?
There are approximately 96 recruiting clinical trials in Kalamazoo, Michigan listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Kalamazoo pay participants?
Most recruiting trials in Kalamazoo compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Kalamazoo?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Kalamazoo?
The most common conditions under active study in Kalamazoo include Malignant Solid Neoplasm (5), Acute Myeloid Leukemia (4), Anatomic Stage II Breast Cancer AJCC v8 (4), B Acute Lymphoblastic Leukemia (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Kalamazoo?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Kalamazoo on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Kalamazoo?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Kalamazoo?
Recruiting research sites in Kalamazoo include Bronson Methodist Hospital, West Michigan Cancer Center, Beacon Kalamazoo Cancer Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Kalamazoo right now?
The largest active categories in Kalamazoo are Cancer & tumors (63), Neurology & pain (3), Cardiovascular (2). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Beacon Kalamazoo?
Beacon Kalamazoo is located at Beacon Kalamazoo - Formerly Borgess Hospital, 1521 Gull Rd, Kalamazoo, MI 49048. Use the Google Maps link in the intro above to get directions.
How do I contact Beacon Kalamazoo?
You can reach Beacon Kalamazoo by phone at (269) 226-7000. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.